Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Clindove Research LLC

Status: Enrolling

Conditions: Prediabetes; Mental Health Disorders; Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease (CKD); Obesity; Cardiovascular Diseases; Endocrine Dysfunction; Metabolic Syndrome

Treatments: Other: Blood Work

Study type: Observational

Funder types: Other

Identifiers

NCT07106879

METCOME062025

Details and patient eligibility

About

DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.

Full description

Eligible participants will undergo screening procedures including laboratory assessments and health questionnaires to determine their suitability for further evaluation in metabolic and/or psychiatric sub-studies. The study does not include any investigational intervention.

Enrollment: 7,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Any participant of age 18 years and over
• Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures.

Exclusion criteria

• Pregnant or breastfeeding individuals
• Individuals having severe cognitive impairment or inability to provide informed consent
• Individuals having acute psychiatric emergencies requiring immediate intervention/hospitalization
• Individuals who are currently participating in another research study that conflicts with pre-screening data collection
• Individuals having known history of drug/alcohol misuse
• Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.

Trial design

7,000 participants in 1 patient group

All Participants

Description:

Participants undergoing metabolic and/or psychiatric assessments through blood work and structured clinical evaluations, as outlined in the study protocol.

Treatment:

Other: Blood Work